9月11日 - ** 制药商Amneal Pharmaceuticals AMRX.O股价上涨2%至10.02美元
** 公司称，美国FDA已批准Amneal的羟苯甲酸钠口服溶液用于治疗7岁及7岁以上嗜睡症患者的嗜睡症或白天过度嗜睡症
** Amneal公司的溶液是爵士制药公司JAZZ.O的睡眠障碍药物Xyrem的仿制药。
** 嗜睡症是一种慢性神经系统疾病，会破坏人体调节睡眠-觉醒周期的能力。
** Amneal公司称，该公司此前一直在限量分销羟甲贝特钠口服溶液的授权仿制药
** 包括盘中走势在内，该股今年累计上涨 25.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.